Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Castor Oil→

Castor Oil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8001-79-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Vegetable oil laxativetriglyceride mixture rich in ricinoleic acid
Mechanism of action
Hydrolysed in the small intestine to ricinoleic acid, which activates prostanoid EP3 receptors on intestinal smooth muscle and increases intestinal motility and fluid secretion.
Indications / reported uses
  • Short-term relief of occasional constipation in adults using authorised oral laxative preparations; not intended for chronic constipation or during pregnancy unless specifically directed by a clinician

Sources: NLM MeSH — Castor oil · PubMed — Ricinoleic acid EP3 receptor laxative mechanism · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Castor Oil Environmental Risk Assessment (ERA) (the Castor Oil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.